CRISPR Therapeutics AG: CEO Kulkarni Samarth exercised 8,333 shares

What happened

• The filing reports that Kulkarni Samarth, CEO, converted or exercised derivative awards for 8,333 shares on Oct 13, 2026 (reported as code M).
• The filing reports a sale of 4,098 shares in an open market or private sale on Oct 14, 2026 at $49.26 per share for $201,867.
• The filing also reports a disposition of 8,333 shares on Oct 13, 2026 in connection with the derivative (reported as code M).

Key details

• Transaction dates and prices: Oct 13, 2026 (exercise/conversion of derivative for 8,333 shares, no price reported); Oct 14, 2026 sale of 4,098 shares at $49.26 for $201,867.
• Shares owned following the transactions: not disclosed in the filing.
• Footnotes: F1 notes each restricted stock unit (RSU) represents a contingent right to one share; F2 states the 4,098-share sale represents shares sold to cover tax withholding required by the company's RSU settlement policy and was not a discretionary trade; F3 describes the RSU grant on Oct 13, 2023 with one-third vesting each year through Oct 13, 2026.
• Filing timeliness: the filing does not indicate a late filing.

Why it may matter

• The filing shows a derivative conversion or exercise on Oct 13, 2026 and a subsequent market sale on Oct 14, 2026; the filing indicates some shares were sold to satisfy tax withholding tied to RSU vesting.
• For derivative exercises, the filing indicates shares were converted and some shares were sold rather than retained (cashless component for tax withholding).
• This filing does not show why the insider traded or why the company acted.